Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 1
2005 1
2006 4
2007 3
2008 3
2009 2
2010 2
2011 2
2012 1
2013 2
2014 2
2017 2
2022 2
Text availability
Article attribute
Article type
Publication date

Search Results

24 results
Results by year
Filters applied: . Clear all
Page 1
Shorter serial intervals in SARS-CoV-2 cases with Omicron BA.1 variant compared with Delta variant, the Netherlands, 13 to 26 December 2021.
Backer JA, Eggink D, Andeweg SP, Veldhuijzen IK, van Maarseveen N, Vermaas K, Vlaemynck B, Schepers R, van den Hof S, Reusken CB, Wallinga J. Backer JA, et al. Among authors: van maarseveen n. Euro Surveill. 2022 Feb;27(6):2200042. doi: 10.2807/1560-7917.ES.2022.27.6.2200042. Euro Surveill. 2022. PMID: 35144721 Free PMC article.
Resistance to protease inhibitors.
van Maarseveen N, Boucher C. van Maarseveen N, et al. In: Geretti AM, editor. Antiretroviral Resistance in Clinical Practice. London: Mediscript; 2006. Chapter 3. In: Geretti AM, editor. Antiretroviral Resistance in Clinical Practice. London: Mediscript; 2006. Chapter 3. PMID: 21249774 Free Books & Documents. Review.
High prevalence of the A2058T macrolide resistance-associated mutation in Mycoplasma genitalium strains from the Netherlands.
Braam JF, Slotboom B, Van Marm S, Severs TT, Van Maarseveen NM, Van Zwet T, Boel ECH, Berkhout H, Hagen F, Van De Bovenkamp JHB, Van Dommelen L, Kusters JG. Braam JF, et al. Among authors: van maarseveen nm. J Antimicrob Chemother. 2017 May 1;72(5):1529-1530. doi: 10.1093/jac/dkw584. J Antimicrob Chemother. 2017. PMID: 28158595 No abstract available.
Telbivudine exerts no antiviral activity against HIV-1 in vitro and in humans.
van Maarseveen NM, Wensing AM, de Jong D, Beilhartz GL, Obikhod A, Tao S, Pingen M, Arends JE, Hoepelman AI, Schinazi RF, Götte M, Nijhuis M. van Maarseveen NM, et al. Antivir Ther. 2011;16(7):1123-30. doi: 10.3851/IMP1912. Antivir Ther. 2011. PMID: 22024528 Free PMC article.
GS-8374, a prototype phosphonate-containing inhibitor of HIV-1 protease, effectively inhibits protease mutants with amino acid insertions.
Grantz Šašková K, Kozíšek M, Stray K, de Jong D, Rezáová P, Brynda J, van Maarseveen NM, Nijhuis M, Cihlár T, Konvalinka J. Grantz Šašková K, et al. Among authors: van maarseveen nm. J Virol. 2014 Mar;88(6):3586-90. doi: 10.1128/JVI.02688-13. Epub 2013 Dec 26. J Virol. 2014. PMID: 24371077 Free PMC article.
Increased risk of infection with SARS-CoV-2 Omicron BA.1 compared with Delta in vaccinated and previously infected individuals, the Netherlands, 22 November 2021 to 19 January 2022.
Eggink D, Andeweg SP, Vennema H, van Maarseveen N, Vermaas K, Vlaemynck B, Schepers R, van Gageldonk-Lafeber AB, van den Hof S, Reusken CB, Knol MJ. Eggink D, et al. Among authors: van maarseveen n. Euro Surveill. 2022 Jan;27(4):2101196. doi: 10.2807/1560-7917.ES.2022.27.4.2101196. Euro Surveill. 2022. PMID: 35086609 Free PMC article.
A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism.
Nijhuis M, van Maarseveen NM, Lastere S, Schipper P, Coakley E, Glass B, Rovenska M, de Jong D, Chappey C, Goedegebuure IW, Heilek-Snyder G, Dulude D, Cammack N, Brakier-Gingras L, Konvalinka J, Parkin N, Kräusslich HG, Brun-Vezinet F, Boucher CA. Nijhuis M, et al. Among authors: van maarseveen nm. PLoS Med. 2007 Jan;4(1):e36. doi: 10.1371/journal.pmed.0040036. PLoS Med. 2007. PMID: 17227139 Free PMC article.
24 results